Intra-Cellular Therapies, Inc.ITCI

Market cap

$13.4B

P/E ratio

	Mar 31, 2013	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Product	-	-	-	-	-	-	-	-	23	82	249	462	681
Grant revenue	-	-	-	-	-	-	-	-	282,226	2	1	2	0
Total revenues, net	-	-	-	-	-	-	-	60,613	23	84	250	464	681
Cost of product sales	-	-	-	-	-	-	-	-	-	-	-	34	57
Selling, general and administrative	-	-	-	-	-	-	-	-	-	-	-	-	504
Research and development	-	23	21	88	94	79	132	89	66	89	135	180	236
Total operating expenses	-	-	-	-	119	103	162	154	254	369	514	624	798
Loss from operations	-	-26,266,852	-30,986,723	-105,813,996	-118,258,891	-102,840,129	-162,266,768	-154,011,850	-231,227,631	-285,688,125	-264	-159	-117
Interest income	-	29,617	303,936	1	3	4	7	6	4	2	7	20	43
Loss before provision for income taxes	-32,100	-	-	-	-115,360,595	-98,834,265	-155,125,811	-147,720,578	-226,992,150	-284,120,035	-256	-139	-74
Income tax expense	-	18,000	1,600	1,600	1	-1,060,851	1,600	1,600	13,513	5,631	0	1	0
Net loss	-32,100	-26,868,198	-30,691,460	-104,793,141	-116,426,268	-97,773,414	-155,127,411	-147,722,178	-227,005,663	-284,125,666	-256	-140	-75
Earnings Per Share, Basic	-	-	-	-	-	-	-	-	-	-	-2.72	-1.46	-0.72
Earnings Per Share, Diluted	-	-	-	-	-	-	-	-	-	-	-2.72	-1.46	-0.72